Arkolith/Insider Trading/XLO/Form 4

Brennan Kevin M.

SVP, FINANCE AND ACCOUNTINGXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Nov 25, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
0 non-derivative · 7 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 21, 2025Grant(A)132K—$0132K
Nov 21, 2025Disposed to issuer(D)55K——0
Nov 21, 2025Grant(A)55K——55K
Nov 21, 2025Disposed to issuer(D)25K——0
Nov 21, 2025Grant(A)25K——25K
Nov 21, 2025Disposed to issuer(D)20K——0
Nov 21, 2025Grant(A)20K——20K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-297207) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML